CDK14 and triple-negative breast carcinoma: To confirm these developmental defects in Cdk14 knockout mice, we made use of a CDK14 antagonist, namely FMF-04-159-2 (hereinafter abbreviated as FMF), which covalently binds to the CDK14 protein with a selective inhibitory effect on the progression of triple-negative breast cancer [8].